TABLE 3.
Risk factors associated with seroconversion after the second vaccine dose in the immunogenicity cohort (n = 856)
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P | OR (95% CI) | P | OR (95% CI) | |
| Age (each additional y of age), y | <0.0001 | 0.994 (0.991-0.996) | <0.0001 | 0.96 (0.94-0.98) |
| Male gender (vs female gender) | <0.0001 | 0.705 (0.589-0.845) | 0.413 | 0.89 (0.67-1.20) |
| Diabetes (vs no diabetes) | <0.0001 | 0.417 (0.261-0.664) | 0.170 | 0.70 (0.42-1.18) |
| Recipient from deceased donor (vs living donor) | <0.0001 | 0.581 (0.490-0.688) | 0.001 | 0.57 (0.41-0.79) |
| Length of transplant, y | 0.148 | 0.990 (0.976-1.004) | – | – |
| Maintenance regimen | 0.079 | 0.847 | ||
| TAC-Pred-AZA | Ref | Ref | ||
| TAC-Pred-MPA | 0.771 (0.628-0.947) | 1.16 (0.82-1.64) | ||
| CSA-Pred-AZA | 0.909 (0.592-1.395) | 1.32 (0.77-2.26) | ||
| TAC-Pred-mTORi | 0.792 (0.529-1.188) | 1.16 (0.69-1.94) | ||
| Others | 0.778 (0.440-1.376) | 1.05 (0.54-2.03) | ||
AZA, azathioprine; CI, confidence interval; CSA, cyclosporine; MPA, mycophenolic acid; mTORi, mechanistic target of rapamycin inhibitor; OR, odds ratio; Pred, prednisone; ref, reference; TAC, tacrolimus.